PolyCAb is under clinical development by Micropharm and currently in Phase I for Clostridioides difficile Infections (Clostridium difficile Associated Disease). According to GlobalData, Phase I drugs for Clostridioides difficile Infections (Clostridium difficile Associated Disease) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PolyCAb’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PolyCAb is under development for the treatment of acute and severe Clostridium difficile infections (CDI). The drug candidate is administered intravenously. The drug candidate is a ovine antisera containing high levels of specific polyclonal antibodies directed against toxic molecules of pathogen.
Micropharm is a developer and manufacturer of ovine polyclonal antibodies targeting infectious diseases. The company manufactures antivenoms and develops various immunotherapeutic products for human and veterinary use. The company offers products which include ViperaTAb, a polyvalent immune fab (Ovine) for the treatment of snakebites from the European common adder (Vipera berus); and EchiTAbG, for the treatment of envenomation by Echis ocellatus. Micropharm’s pipeline products include ColchiBIND, ViperaVet, OraCAb, EBOTAb and PolyCAb. The company offers products for the treatment of colchicine toxicity, envenomed in dogs and severe clostridium difficile infections, among others. It also offers contract development, manufacturing and sterile filling services. Micropharm is headquartered in Newcastle Emlyn, Carmarthenshire, the UK.
For a complete picture of PolyCAb’s drug-specific PTSR and LoA scores, buy the report here.